Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 5/20 | 0.37 |
| ▸ | NECTIN4 | Q96NY8 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20846180 | 0.97 | CYP3A4 (0.48) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL19084353 | 0.96 | CYP3A4 (0.49) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL19084307 | 0.96 | CYP3A4 (0.49) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL26270646 | 0.93 | CYP3A4 (0.47) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL20846080 | 0.92 | CYP3A4 (0.44) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL19084308 | 0.91 | CYP3A4 (0.46) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL17987755 | 0.90 | CYP3A4 (0.48) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL20800164 | 0.90 | CYP3A4 (0.47) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL17987724 | 0.90 | CYP3A4 (0.47) | CYP3A4FOLH1TTRFAPNECTIN4 | |
| SCHEMBL20800166 | 0.90 | CYP3A4 (0.48) | CYP3A4FOLH1TTRFAPNECTIN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | HANGZHOU ADCORIS BIOPHARMA CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | ERBB2, EGFR, ERBB3 | CYP3A4 3734/4885FOLH1 111/4885TTR 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.